GlassScriptPhysician profile
Alejandra P Cabral
NPI 1699222620
$1,218.04
in general payments reported to CMS, 2019-2025
21 companies · $527 in 2025
The $527 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.56 · 2023: $306 · 2024: $328 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.49 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217.56 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $171.78 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Gilead Sciences, INC. | $138.86 | 2021-2025 | Yeztugo |
| Xeris Pharmaceuticals, INC. | $99.56 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Glaxosmithkline, LLC. | $91.49 | 2024-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $88.90 | 2024 | Veozah |
| Viiv Healthcare Company | $44.20 | 2024-2025 | Dovato, Apretude |
| Edwards Lifesciences Corporation | $43.19 | 2025 | Sapien 3 Ultra Resilia |
| Scilex Pharmaceuticals INC. | $40.10 | 2025 | |
| Organon LLC | $34.79 | 2021 | |
| Abbvie INC. | $29.19 | 2023 | |
| Coopersurgical, INC. | $27.14 | 2024 | Paragard T 380a |
| Seqirus USA INC | $27.09 | 2024 | Fluad, Flucelvax |
| Insulet Corporation | $26.60 | 2023 | Omnipod |
| Phadia US INC. | $23.55 | 2024 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $23.55 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $21.60 | 2024 | Watchman Flx |
| Abbott Laboratories | $21.41 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $19.57 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amgen INC. | $14.84 | 2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Cabral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.